Focused On-demand Library for Atrial natriuretic peptide-converting enzyme

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y5Q5

UPID:

CORIN_HUMAN

Alternative names:

Corin; Heart-specific serine proteinase ATC2; Pro-ANP-converting enzyme; Transmembrane protease serine 10

Alternative UPACC:

Q9Y5Q5; B0ZBE3; Q2TBD2; Q4W5E5; Q4W5G6; Q9UHY2

Background:

The Atrial natriuretic peptide-converting enzyme, known as Corin, is a serine-type endopeptidase crucial for processing natriuretic peptides such as ANP and BNP. These peptides play a pivotal role in regulating blood pressure, promoting natriuresis, diuresis, and vasodilation. Corin's activity extends to facilitating trophoblast invasion and spiral artery remodeling during pregnancy, and it also influences sodium reabsorption in the kidneys.

Therapeutic significance:

Corin's involvement in the pathophysiology of Pre-eclampsia/eclampsia 5, a hypertensive disorder of pregnancy, underscores its potential as a therapeutic target. Understanding Corin's role could pave the way for innovative treatments aimed at mitigating maternal and fetal risks associated with this condition.